400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Epigenetics / HDAC / 帕比司他
CAS No.: 404950-80-7
Synonyms: LBH589;NVP-LBH589;trade name Farydak
Panobinostat is a broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay.
生物活性
靶点 | HDAC IC50:5nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02506959 | Plasma Cell Leukemia ... more >> Plasmacytoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Collapse << | Phase 2 | Recruiting | September 14, 2019 | United States, Texas ... more >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Yago L. Nieto 713-792-8750 ynieto@mdanderson.org Principal Investigator: Yago L. Nieto Collapse << |
NCT00449761 | Leukemia, Myeloid, Chronic | Phase 2 Phase 3 | Completed | - | - |
NCT01055483 | Acute Myeloid Leukemia | Phase 1 | Completed | - | France ... more >> Novartis Investigative Site Paris Cedex 4, France, 75181 Novartis Investigative Site Paris, France, 75475 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 Collapse << |
实验方案
技术信息
CAS号 | 404950-80-7 | 储存条件 |
|
|||||||||||||
分子式 | C21H23N3O2 | 运输 | 蓝冰 | |||||||||||||
分子量 | 349.43 | 别名 | LBH589;NVP-LBH589;trade name Farydak;帕比司他 | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
769-P | 10/25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with ritonavir | 25279191 |
769-P | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis combined ritonavir | 25279191 |
769-P | 25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with bortezomib | 25176354 |
769-P | 50 nM | Colony Formation Assay | 7-14 d | suppressed colony formation significantly combined with with bortezomib | 25176354 |
769-P | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis | 25176354 |
786-O | 10/25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with ritonavir | 25279191 |
786-O | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis combined ritonavir | 25279191 |
A549 | 10/15/20 nM | Growth Inhibition Assay | 72 h | enhances the antiproliferative effect of erlotinib | 26675484 |
ACHN | 10/25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with ritonavir | 25279191 |
ACHN | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis combined ritonavir | 25279191 |
ACHN | 25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with bortezomib | 25176354 |
ACHN | 50 nM | Colony Formation Assay | 7-14 d | suppressed colony formation significantly combined with with bortezomib | 25176354 |
ACHN | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis | 25176354 |
AML3 | 0-1 μM | Function Assay | 24 h | induces DNA fragmentation in a dose-dependent manner | 25612941 |
BHP2-7 | - | Growth Inhibition Assay | - | IC50=37 ± 6 nM | 23824064 |
BT-549 | 10 nM | Morphological Crystal Violet (CV) Assay | 3 d | alters cell morphology | 24810497 |
C643 | - | Growth Inhibition Assay | - | IC50=71 ± 10 nM | 23824064 |
Caki-1 | 10/25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with ritonavir | 25279191 |
Caki-1 | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis combined ritonavir | 25279191 |
Caki-1 | 25/50 nM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner synergistically with bortezomib | 25176354 |
Caki-1 | 50 nM | Colony Formation Assay | 7-14 d | suppressed colony formation significantly combined with with bortezomib | 25176354 |
Caki-1 | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis | 25176354 |
Cal62 | - | Growth Inhibition Assay | - | IC50=33 ± 4 nM | 23824064 |
Capan-1 | 25/50/100 nM | Function Assay | 8/24/48 h | downregulated Ron mRNA and protein expression and downstream signaling | 23922886 |
Capan-1 | 25/50/100 nM | Growth Inhibition Assay | 48 h | reduces cell growth in a dose-dependent manner | 23922886 |
Capan-1 | 25/50/100 nM | Apoptosis Assay | 48 h | induces cell growth in a dose-dependent manner | 23922886 |
CFPAC-1 | 25/50/100 nM | Function Assay | 8/24/48 h | downregulated Ron mRNA and protein expression and downstream signaling | 23922886 |
CFPAC-1 | 25/50/100 nM | Growth Inhibition Assay | 48 h | reduces cell growth in a dose-dependent manner | 23922886 |
CFPAC-1 | 25/50/100 nM | Apoptosis Assay | 48 h | induces cell growth in a dose-dependent manner | 23922886 |
cH630 5-FU-res | - | Growth Inhibition Assay | 72 h | IC50=15.5 ± 1.2 nM | 23299388 |
CTS | 0–40 nM | Apoptosis Assay | 48 h | induces apoptosis in a dose-dependent manner | 24244429 |
dHCT116 p21−/− | - | Growth Inhibition Assay | 72 h | IC50=5.9 ± 1.3 nM | 23299388 |
eSW620 | - | Growth Inhibition Assay | 72 h | IC50=9.1 ± 2.1 nM | 23299388 |
FaDu | 100 nM | Growth Inhibition Assay | 8/10/12 h | displayed a significant and prolonged G2/M arrest at 8 and 12 h post release | 24026482 |
FaDu | 100 nM | Function Assay | 2/4/8/12 h | induced p21Waf1/Cip1 expression | 24026482 |
G401 | 0.01–10.0 μM | Growth Inhibition Assay | 24 h | IC50=143.02 nM | 26176219 |
G401 | 50 nM | Cell Viability Assay | 1–4 d | reduces cell survival in a time dependent manner | 26176219 |
G401 | 50/100 nM | Apoptosis Assay | 24 h | induces cell apoptosis in a dose-dependent manner | 26176219 |
G401 | 50/100 nM | Function Assay | 24 h | shows the induction of DNA fragmentation | 26176219 |
G401 | 50/100 nM | Function Assay | 24 h | induces cell cycle disorder | 26176219 |
H630 | - | Growth Inhibition Assay | 72 h | IC50=12.4 ± 3.1 nM | 23299388 |
H929 | 2/4/6 nM | Cell Survival Assay | 48 h | induces a significant decrease in the cell growth | 26000292 |
HCC827 | 5/7.5/10 nM | Growth Inhibition Assay | 72 h | enhances the antiproliferative effect of erlotinib | 26675484 |
HCC827 | 10 nM | Growth Inhibition Assay | 48 h | enhances cisplatin sensitivity | 25944617 |
HCC-LM3 | 1-1000 nM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time- and dose-dependent manner | 24093956 |
HCC-LM3 | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis significantly in a caspase-dependent manner by cleavage of caspases 3, 8 and 9 | 24093956 |
HCC-LM3 | 50/100 nM | Function Assay | 24 h | decreases the levels of p-STAT3 and p-Akt | 24093956 |
HCC-LM3 | 50/100 nM | Function Assay | 24 h | downregulates Bcl-xL expression | 24093956 |
HCT116 | - | Growth Inhibition Assay | 72 h | IC50=10.7 ± 2.2 nM | 23299388 |
HCT116 p53−/− | - | Growth Inhibition Assay | 72 h | IC50=8.6 ± 1.7 nM | 23299388 |
HCT8 | - | Growth Inhibition Assay | 72 h | IC50=12.9 ± 1.9 nM | 23299388 |
HepG2 | 0-10 μM | Growth Inhibition Assay | 0-4 d | inhibits cell growth in both time- and dose-dependent manner | 26702784 |
HepG2 | 50 nM | Function Assay | 24-72 h | induced activation of caspase 3 after 24 h | 26702784 |
HepG2 | 1-1000 nM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time- and dose-dependent manner | 24093956 |
HepG2 | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis significantly in a caspase-dependent manner by cleavage of caspases 3, 8 and 9 | 24093956 |
HepG2 | 50/100 nM | Function Assay | 24 h | decreases the levels of p-STAT3 and p-Akt | 24093956 |
HepG2 | 50/100 nM | Function Assay | 24 h | downregulates Bcl-xL expression | 24093956 |
HN22 | 0-20 nM | Growth Inhibition Assay | 24/48 h | inhibits cell viability in both time- and dose- dependent manner | 23877235 |
HN22 | 0-20 nM | Apoptosis Assay | 48 h | induces cell apoptosis | 23877235 |
HN22 | 0-20 nM | Growth Inhibition Assay | 48 h | induces G1 phase cell cycle arrest | 23877235 |
HN22 | 0-20 nM | Function Assay | 48 h | suppresses Sp1 expression | 23877235 |
HSC4 | 0-20 nM | Growth Inhibition Assay | 24/48 h | inhibits cell viability in both time- and dose- dependent manner | 23877235 |
HSC4 | 0-20 nM | Apoptosis Assay | 48 h | induces cell apoptosis | 23877235 |
HSC4 | 0-20 nM | Growth Inhibition Assay | 48 h | induces G1 phase cell cycle arrest | 23877235 |
HSC4 | 0-20 nM | Function Assay | 48 h | suppresses Sp1 expression | 23877235 |
HT29 | 0-10 μM | Growth Inhibition Assay | 0-4 d | inhibits cell growth in both time- and dose-dependent manner | 26702784 |
HT29 | 50 nM | Function Assay | 24-72 h | induced activation of caspase 3 after 48 h | 26702784 |
HT29 | - | Growth Inhibition Assay | 72 h | IC50=16.3 ± 2.3 nM | 23299388 |
Hth7 | - | Growth Inhibition Assay | - | IC50=15 ± 2 nM | 23824064 |
Hth83 | - | Growth Inhibition Assay | - | IC50=34 ± 5 nM | 23824064 |
J89GFP | - | Growth Inhibition Assay | - | EC50=49.85 ± 12.65 nM | 26563568 |
L3.6pl | 25/50/100 nM | Function Assay | 8/24/48 h | downregulated Ron mRNA and protein expression and downstream signaling | 23922886 |
L3.6pl | 25/50/100 nM | Growth Inhibition Assay | 48 h | reduces cell growth in a dose-dependent manner | 23922886 |
L3.6pl | 25/50/100 nM | Apoptosis Assay | 48 h | induces cell growth in a dose-dependent manner | 23922886 |
LNCaP | 0-5 μM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time- and dose-dependent manner | 23991216 |
LoVo | - | Growth Inhibition Assay | 72 h | IC50=5.1 ± 0.6 nM | 23299388 |
MCF-7 | 10 nM | Morphological Crystal Violet (CV) Assay | 3 d | alters cell morphology | 24810497 |
MCF-7 | 5-50 nM | Function Assay | 24 h | reduced the level of expression of ERα, PR and FoxA1 | 24366407 |
MDA-MB-231 | 10 nM | Morphological Crystal Violet (CV) Assay | 3 d | alters cell morphology | 24810497 |
ML-1 | 0-1 μM | Function Assay | 24 h | induces DNA fragmentation in a dose-dependent manner | 25612941 |
ML-1 | 1 μM | Function Assay | 24 h | increases caspase-3 activity 4-fold | 25612941 |
NCI-H23 | 10 nM | Growth Inhibition Assay | 48 h | enhances cisplatin sensitivity | 25944617 |
NCI-H460 | 10/20/30 nM | Growth Inhibition Assay | 72 h | enhances the antiproliferative effect of erlotinib | 26675484 |
OCI-AML3 | 0–40 nM | Apoptosis Assay | 48 h | induces apoptosis in a dose-dependent manner | 24244429 |
OPM2 | 2/4/6 nM | Cell Survival Assay | 48 h | induces a significant decrease in the cell growth | 26000292 |
OS-RC-2 | 0-1000 nM | Cell Viability Assay | 24/48/72 h | decreases cell viability in both time- and dose-dependent manner | 24144737 |
OS-RC-2 | 50 nM | Growth Inhibition Assay | 48 h | induces G2/M arrest | 24144737 |
OS-RC-2 | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis | 24144737 |
PC3 | 0-100 nM | Apoptosis Assay | 24/48 h | induces apoptosis in a dose-dependent manner | 24163230 |
PC3 | 0-100 nM | Growth Inhibition Assay | 24/48 h | induces accumulation of subG1 population | 24163230 |
PC3 | 0-100 nM | Function Assay | 24 h | suppresses expression of activated ATM, Akt and Erk1/2 protein | 24163230 |
PC-3 | 0-10 μM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time- and dose-dependent manner | 23991216 |
PC3-AR | 0-100 nM | Apoptosis Assay | 24/48 h | induces apoptosis in both time- and dose-dependent manner | 24163230 |
PC3-AR | 0-100 nM | Growth Inhibition Assay | 24/48 h | induces cell cycle arrest in the G2M phase | 24163230 |
PC3-AR | 0-100 nM | Function Assay | 24 h | suppresses expression of activated ATM, Akt and Erk1/2 protein | 24163230 |
RKO | - | Growth Inhibition Assay | 72 h | IC50=7.9 ± 2.2 nM | 23299388 |
RPMI 8226 | 2/4/6 nM | Cell Survival Assay | 48 h | induces a significant decrease in the cell growth | 26000292 |
RPMI 8226 | 4 nM | Apoptosis Assay | 24/48 h | induces cell apoptosis in a time-dependent manner | 26000292 |
RPMI-8226vr10 | 0-1 μM | Function Assay | 24 h | induces DNA fragmentation in a dose-dependent manner | 25612941 |
RPMI-8226vr10 | 1 μM | Function Assay | 24 h | increases caspase-3 activity 2.5-fold | 25612941 |
RWPE-1 | 0-20 μM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time- and dose-dependent manner | 23991216 |
SK-N-AS | - | Growth Inhibition Assay | 24 h | IC50=37.1 ± 2.4 nM | 25308916 |
SK-N-AS | 0–80 nM | Growth Inhibition Assay | 48 h | IC50=27.4 nM | 24098799 |
SK-N-AS | 0–80 nM | Apoptosis Assay | 48 h | potently induced apoptosis in a dose-dependent fashion | 24098799 |
SK-N-AS | 0–80 nM | Function Assay | 48 h | induces a dose-dependent cleavage of caspase 3 and PARP | 24098799 |
SK-N-BE | 0–80 nM | Growth Inhibition Assay | 48 h | IC50=75.4 nM | 24098799 |
SK-N-BE | 0–40 nM | Apoptosis Assay | 48 h | potently induced apoptosis in a dose-dependent fashion | 24098799 |
SK-N-BE | 0–40 nM | Function Assay | 48 h | induces a dose-dependent cleavage of caspase 3 and PARP | 24098799 |
SK-N-BE (2) | - | Growth Inhibition Assay | 24 h | IC50=104.0 ± 7.8 nM | 25308916 |
SK-N-BE (2), MK PAN | - | Growth Inhibition Assay | 24 h | IC50=382.0 ± 43.2 nM | 25308916 |
SK-N-BE (2), PAN MK | - | Growth Inhibition Assay | 24 h | IC50=104.0 ± 7.8 nM | 25308916 |
SK-N-DZ | - | Growth Inhibition Assay | 24 h | IC50=17.1 ± 0.4 nM | 25308916 |
SK-N-DZ | 0–80 nM | Growth Inhibition Assay | 48 h | IC50=21.9 nM | 24098799 |
SK-N-DZ | 0–80 nM | Apoptosis Assay | 48 h | potently induced apoptosis in a dose-dependent fashion | 24098799 |
SK-N-DZ | 0–80 nM | Function Assay | 48 h | induces a dose-dependent cleavage of caspase 3 and PARP | 24098799 |
SK-NEP-1 | 0.01–10.0 μM | Growth Inhibition Assay | 24 h | IC50=76.34 nM | 26176219 |
SK-NEP-1 | 50 nM | Cell Viability Assay | 1–4 d | reduces cell survival in a time dependent manner | 26176219 |
SK-NEP-1 | 50/100 nM | Apoptosis Assay | 24 h | induces cell apoptosis in a dose-dependent manner | 26176219 |
SK-NEP-1 | 50/100 nM | Function Assay | 24 h | shows the induction of DNA fragmentation | 26176219 |
SK-NEP-1 | 50/100 nM | Function Assay | 24 h | induces cell cycle disorder | 26176219 |
SK-N-SH | 0–80 nM | Growth Inhibition Assay | 48 h | IC50=72.3 nM | 24098799 |
SK-N-SH | 0–40 nM | Apoptosis Assay | 48 h | potently induced apoptosis in a dose-dependent fashion | 24098799 |
SK-N-SH | 0–40 nM | Function Assay | 48 h | induces a dose-dependent cleavage of caspase 3 and PARP | 24098799 |
SMMC-7721 | 1-1000 nM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time- and dose-dependent manner | 24093956 |
SMMC-7721 | 50 nM | Apoptosis Assay | 48 h | induces cell apoptosis significantly in a caspase-dependent manner by cleavage of caspases 3, 8 and 9 | 24093956 |
SMMC-7721 | 50/100 nM | Function Assay | 24 h | decreases the levels of p-STAT3 and p-Akt | 24093956 |
SMMC-7721 | 50/100 nM | Function Assay | 24 h | downregulates Bcl-xL expression | 24093956 |
SW1736 | - | Growth Inhibition Assay | - | IC50=35 ± 8 nM | 23824064 |
SW480 | - | Growth Inhibition Assay | 72 h | IC50=17.5 ± 0.8 nM | 23299388 |
T238 | - | Growth Inhibition Assay | - | IC50=1,500 ± 200 nM | 23824064 |
T241 | - | Growth Inhibition Assay | - | IC50=65 ± 7 nM | 23824064 |
T351 | - | Growth Inhibition Assay | - | IC50=50 ± 10 nM | 23824064 |
THP89GFP | - | Growth Inhibition Assay | - | EC50=19.34 ± 6.43 nM | 26563568 |
U266 | 2/4/6 nM | Cell Survival Assay | 48 h | induces a significant decrease in the cell growth | 26000292 |
U937 | 0–40 nM | Apoptosis Assay | 48 h | induces apoptosis in a dose-dependent manner | 24244429 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02506959 | Plasma Cell Leukemia ... more >> Plasmacytoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Collapse << | Phase 2 | Recruiting | September 14, 2019 | United States, Texas ... more >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Yago L. Nieto 713-792-8750 ynieto@mdanderson.org Principal Investigator: Yago L. Nieto Collapse << |
NCT00449761 | Leukemia, Myeloid, Chronic | Phase 2 Phase 3 | Completed | - | - |
NCT01055483 | Acute Myeloid Leukemia | Phase 1 | Completed | - | France ... more >> Novartis Investigative Site Paris Cedex 4, France, 75181 Novartis Investigative Site Paris, France, 75475 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 Collapse << |
NCT00936611 | Waldenstrom's Macroglobulinemi... more >>a Collapse << | Phase 2 | Active, not recruiting | December 2021 | United States, Colorado ... more >> Rocky Mountain Cancer Centers Denver, Colorado, United States, 80220 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT00880269 | Refractory Leukemia ... more >> Acute Myelogenous Leukemia Collapse << | Phase 2 | Completed | - | - |
NCT02802163 | Multiple Myeloma | Phase 1 Phase 2 | Withdrawn(study drug unavailab... more >>le) Collapse << | December 2020 | - |
NCT00493766 | Hormone Refractory Prostate Ca... more >>ncer Collapse << | Phase 1 | Terminated(Because of a strate... more >>gic decision by Novartis) Collapse << | - | United States, Massachusetts ... more >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115-6-84 United States, Missouri Washing University School of Medicine St. Louis, Missouri, United States, 63110 United States, Nevada Nevada Cancer Institute Las Vegas, Nevada, United States, 89135 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27705 Collapse << |
NCT02145715 | Multiple Myeloma | Phase 1 Phase 2 | Unknown | January 2016 | United Kingdom ... more >> Birmingham Heartlands Hospital Birmingham, UK, United Kingdom, B9 5SS Royal Liverpool University Hospital Liverpool, United Kingdom, L7 8XP St Bartholomew's Hospital London, United Kingdom, EC1A 7BE University College London Hospitals NHS Foundation Trust London, United Kingdom, WC1E 6AG Guy's Hospital London, United Kingdom Collapse << |
NCT00880269 | - | - | Completed | - | - |
NCT00918333 | Adult Nasal Type Extranodal NK... more >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma B-cell Adult Acute Lymphoblastic Leukemia Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Nodal Marginal Zone B-cell Lymphoma Post-transplant Lymphoproliferative Disorder Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Multiple Myeloma Splenic Marginal Zone Lymphoma T-cell Adult Acute Lymphoblastic Leukemia Waldenström Macroglobulinemia Collapse << | Phase 1 Phase 2 | Active, not recruiting | December 2018 | United States, Arizona ... more >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Maryland Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse << |
NCT00918333 | - | - | Active, not recruiting | - | - |
NCT00738751 | Lung Cancer H... more >>ead and Neck Cancer Collapse << | Phase 1 | Completed | - | United States, Florida ... more >> H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 Collapse << |
NCT01111526 | Graft-Versus-Host Disease | Phase 1 Phase 2 | Completed | - | United States, Florida ... more >> H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Collapse << |
NCT00878436 | Prostate Cancer ... more >> Prostatic Neoplasms Collapse << | Phase 1 Phase 2 | Completed | - | United States, New Jersey ... more >> The Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York North Shore University Hospital-Monter Cancer Center Lake Success, New York, United States, 11042 NYU Cancer Center New York, New York, United States, 10016 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Collapse << |
NCT01111526 | - | - | Completed | - | - |
NCT00777335 | Breast Cancer | Phase 2 | Terminated(Very low recruiteme... more >>nt rate.) Collapse << | - | United States, California ... more >> UCLA Los Angeles, California, United States, 90095-1678 Collapse << |
NCT01055795 | Advanced Solid Tumors | Phase 1 | Completed | - | United States, North Carolina ... more >> Duke University Medical Center Durham, North Carolina, United States, 27710 Collapse << |
NCT00873002 | Liver Cancer | Phase 1 | Terminated(Dose Limiting Toxic... more >>ity) Collapse << | - | United States, Ohio ... more >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Collapse << |
NCT02204553 | - | - | - | - | - |
NCT01090973 | Non-Hodgkin's Lymphoma | Phase 2 | Terminated(Pharmaceutical comp... more >>any request.) Collapse << | - | United States, Florida ... more >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Collapse << |
NCT00878436 | - | - | Completed | - | - |
NCT01090973 | - | - | Terminated(Pharmaceutical comp... more >>any request.) Collapse << | - | - |
NCT00788931 | HER-2 Positive Breast Cancer ... more >> Metastatic Breast Cancer Collapse << | Phase 1 | Completed | - | United States, Alabama ... more >> Novartis Investigative Site Mobile, Alabama, United States, 36688 Australia, South Australia Novartis Investigative Site Woodville, South Australia, Australia, 5011 Belgium Novartis Investigative Site Bruxelles, Belgium, 1000 Novartis Investigative Site Liege, Belgium, 4000 Italy Novartis Investigative Site Macerata, MC, Italy, 62100 Novartis Investigative Site Aviano, PN, Italy, 33081 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1066 CX Collapse << |
NCT00859222 | - | - | Completed | - | - |
NCT01169636 | Hodgkin's Lymphoma | Phase 1 Phase 2 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01083602 | Relapsed and Bortezomib Refrac... more >>tory Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma in Relapse Collapse << | Phase 2 | Completed | - | United States, California ... more >> University of California at Los Angeles Los Angeles, California, United States, 90095 Stanford University Medical Center Division of Hematology Stanford, California, United States, 94305-5826 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States, 30322 Georgia Regents University MedCollege of GA Cancer Ctr 2 Augusta, Georgia, United States, 30912 United States, Illinois Hematology/Oncology of the North Shore Orchard Healthcare Res. Inc. Skokie, Illinois, United States, 60076 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New Jersey Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2) Somerset, New Jersey, United States, 08873 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, North Carolina Duke University Medical Center Dept. of DUMC (4) Durham, North Carolina, United States, 27710 United States, Tennessee Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt UMC Nashville, Tennessee, United States, 37212 United States, Texas MD Anderson Cancer Center/University of Texas MD Anderson CC Houston, Texas, United States, 77030 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Collapse << |
NCT00859222 | Malignant Glioma | Phase 1 Phase 2 | Completed | - | United States, Illinois ... more >> Northwestern University Chicago, Illinois, United States, 60611 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth-Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Virginia University of Virginia, Department of Neurology Charlottesville, Virginia, United States, 22908 Collapse << |
NCT01083602 | - | - | Completed | - | - |
NCT00532389 | Multiple Myeloma | Phase 1 | Completed | - | United States, Florida ... more >> Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch Miami Shores, Florida, United States, 33138 United States, Massachusetts Dana Farber Cancer Institute Clinical Research Coordinator Boston, Massachusetts, United States, 02115 United States, New Jersey Hackensack University Medical Center Multiple Myeloma Division Hackensack, New Jersey, United States, 07601 United States, Washington Swedish Medical Center Dept.ofSwedishMedicalCtr. Seattle, Washington, United States Australia, Australian Capital Territory Novartis Investigative Site Canberra, Australian Capital Territory, Australia, 2606 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H1T 2M4 Germany Novartis Investigative Site Berlin, Germany, 10117 Novartis Investigative Site Kiel, Germany, 24105 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site München, Germany, 80336 Novartis Investigative Site Wuerzburg, Germany, 97070 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Torino, TO, Italy, 10126 Spain Novartis Investigative Site Salamanca, Castilla y Leon, Spain, 37007 Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Collapse << |
NCT00777335 | - | - | Terminated(Very low recruiteme... more >>nt rate.) Collapse << | - | - |
NCT02676323 | Acute Myeloid Leukemia ... more >> Myelodysplastic Syndrome Collapse << | Phase 1 | Terminated(Slow accrual) | - | United States, California ... more >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 Rady Children's Hospital and Health Center San Diego, California, United States, 92123 United States, Michigan Children's Hospital of Michigan Detroit, Michigan, United States, 48201 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Cook Children's Medical Center Fort Worth, Texas, United States, 76104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Collapse << |
NCT01005797 | Renal Cancer ... more >>Non Small Cell Lung Cancer (NSCLC) Soft Tissue Sarcoma Collapse << | Phase 1 | Completed | - | United States, South Carolina ... more >> Medical University of South Carolina Hollings Cancer Center Charleston, South Carolina, United States, 29425 Collapse << |
NCT02057640 | Multiple Myeloma ... more >> Kahler Disease Plasma-Cell Myeloma Myelomatosis Collapse << | Phase 1 Phase 2 | Active, not recruiting | December 2018 | United States, Ohio ... more >> University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Collapse << |
NCT00686218 | Leukemia | Phase 1 | Completed | - | United States, California ... more >> City of Hope Medical Center Duarte, California, United States, 91010-3000 South Pasadena Cancer Center South Pasadena, California, United States, 91030 United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Collapse << |
NCT00445068 | Multiple Myeloma | Phase 2 | Terminated | - | - |
NCT02290431 | Relapse/Refractory Multiple My... more >>eloma Collapse << | Phase 2 | Recruiting | July 8, 2019 | Japan ... more >> Nagoya City University Hospital Recruiting Nagoya City, Aichi, Japan, 467-8602 Novartis Investigative Site Completed Kashiwa-city, Chiba, Japan, 277-8567 Matsuyama Red Cross Hospital Recruiting Matsuyama-City, Ehime, Japan, 790-8524 Novartis Investigative Site Terminated Fukuoka city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Recruiting Ogaki-city, Gifu, Japan, 503-8502 Gunma University Hospital Recruiting Maebashi-city, Gunma, Japan, 371-8511 Principal Investigator: Hiroshi Handa, M.D. Novartis Investigative Site Recruiting Shibukawa-city, Gunma, Japan, 377-0280 Novartis Investigative Site Completed Kure-city, Hiroshima, Japan, 737-0023 Kobe City Medical Center General Hospital Recruiting Kobe, Hyogo, Japan, 650-0047 Mito Medical Center Recruiting Higashiibaraki-gun, Ibaraki, Japan, 311-3193 University Hospital, Kyoto Prefectural, University of Medicine Recruiting Kamigyo-ku, Kyoto, Japan, 602-8566 Novartis Investigative Site Recruiting Sendai-shi, Miyagi, Japan, 983 8520 Niigatq Cancer Ce3nter Hospital Recruiting Kawagishi-cho, Chuo-ku, Niigata, Japan, 951-8566 Novartis Investigative Site Completed Okayama-city, Okayama, Japan, 701-1192 Osaka University Hospital Recruiting Yamadaoka, Suita-City, Osaka, Japan, 565-0871 Novartis Investigative Site Completed Utsunomiya-shi, Tochigi, Japan, 320-0834 Tokushima University Hospital Recruiting Tokushima-City, Tokushima, Japan, 770-8503 Novartis Investigative Site Completed Koto-ku, Tokyo, Japan, 135 8550 Japanese Red Cross Medical Center Recruiting Shibuya-Ku, Tokyo, Japan, 150-8935 Center Hospital of the National Center for Global Health and Medicine Recruiting Shinjuku-ku, Tokyo, Japan, 162-8655 Principal Investigator: Akiyoshi Miwa, M.D. Novartis Investigative Site Recruiting Tachikawa, Tokyo, Japan, 190-0014 Novartis Investigative Site Recruiting Aomori, Japan, 030 8553 Collapse << |
NCT01324635 | Recurrent Glioma ... more >> High-grade Meningioma Brain Metastasis Collapse << | Phase 1 | Terminated(Arm A - reached goa... more >>l; Arm B - poor accrual) Collapse << | - | United States, Pennsylvania ... more >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Collapse << |
NCT03256045 | Recurrent Plasma Cell Myeloma ... more >> Refractory Plasma Cell Myeloma Collapse << | Phase 2 | Recruiting | May 16, 2024 | United States, Washington ... more >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-606-7273 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker Collapse << |
NCT01034657 | - | - | Terminated(The study was termi... more >>nated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.) Collapse << | - | - |
NCT00667862 | Prostate Cancer | Phase 2 | Completed | - | United States, Maryland ... more >> University of Maryland Baltimore, Maryland, United States, 21201 Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Missouri Washington University St. Louis, Missouri, United States, 63130 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53706-1481 Collapse << |
NCT01034657 | Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated(The study was termi... more >>nated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.) Collapse << | - | Germany ... more >> Novartis Investigative Site Mannheim, Baden-Württemberg, Germany, 68305 Novartis Investigative Site Berlin, Germany, 12203 Novartis Investigative Site Bonn, Germany, 53105 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Duesseldorf, Germany, 40225 Novartis Investigative Site Duisburg, Germany, 47166 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Goettingen, Germany, 37075 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Muenchen, Germany, 81675 Novartis Investigative Site Ulm, Germany, 89081 Collapse << |
NCT02756663 | Multiple Myeloma | Phase 2 | Withdrawn | February 2021 | - |
NCT01159418 | Advanced Solid Tumors | Phase 1 | Unknown | March 2012 | Switzerland ... more >> Huniversitätsspitals Basel Basel, Switzerland, 4031 Istituto Oncologico della Svizzera Italiana Bellinzona, Switzerland, 6500 Mèdecin Adjoint, ME - CePO, CHUV Lausanne, Switzerland, 1011 Collapse << |
NCT00472368 | Cancer Patients With Advanced ... more >>Solid Tumors Including Lymphoma or Chronic Hematological Malignancies Collapse << | Phase 1 | Completed | - | United States, New York ... more >> Novartis Investigative Site Buffalo, New York, United States, 14263 Collapse << |
NCT00490776 | Cutaneous T-Cell Lymphoma | Phase 2 Phase 3 | Completed | - | United States, Alabama ... more >> University of Alabama at Birmingham/ The Kirklin Clinic Birmingham, Alabama, United States, 35233 United States, California UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology Los Angeles, California, United States, 90095 United States, Colorado University of Colorado Health Sciences Center/Anschutz Cancer Pavillion Aurora, Colorado, United States, 80010 United States, Florida Florida Academic Dermatology Centers Miami, Florida, United States, 33136 United States, Georgia Medical College of Georgia Augusta, Georgia, United States, 30912 United States, Illinois Rush Presbyterian Hospital/St. Luke's Medical Center Chicago, Illinois, United States, 60612 United States, Missouri St. Louis University Cancer Cennter St. Louis, Missouri, United States, 63110 United States, Nebraska Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, New York Our Lady of Mercy Medical Center/Comprehensive Cancer Center Bronx, New York, United States, 10466 Roswell Park Cancer Institute Buffalo, New York, United States, 14263 NYU Clinical Cancer Center New York, New York, United States, 10016 United States, North Carolina Wake University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Oklahoma University of Oklahoma-Tulsa Tulsa, Oklahoma, United States, 74104 United States, Oregon Craig Okada Portland, Oregon, United States, 97239 United States, Pennsylvania University of Pittsburg Medical Center Pittsburg, Pennsylvania, United States, 15213 United States, Tennessee The Jones Clinic Germantown, Tennessee, United States, 38138 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109-102 Collapse << |
NCT01238692 | Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | December 2016 | Canada, Nova Scotia ... more >> Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada, H3T 1E2 Canada, Ontario Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Sacré-Cœur Hospital Montreal, Quebec, Canada, H4J 1C5 Collapse << |
NCT02588339 | Graft Versus Host Disease ... more >> GVHD Collapse << | Phase 2 | Active, not recruiting | December 2020 | United States, Florida ... more >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Collapse << |
NCT01056601 | - | - | Terminated(Funding not availab... more >>le) Collapse << | - | - |
NCT01056601 | Pancreatic Cancer | Phase 2 | Terminated(Funding not availab... more >>le) Collapse << | - | United States, Minnesota ... more >> Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States, 55455 Collapse << |
NCT01032148 | Hodgkin's Lymphoma ... more >> Non-Hodgkin's Lymphoma Collapse << | Phase 1 | Terminated(lack of funding) | - | United States, New York ... more >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Collapse << |
NCT02720510 | - | - | Terminated(A study was termina... more >>ted due to low enrollment.) Collapse << | - | - |
NCT00412997 | Tumors Cutane... more >>ous T-Cell Lymphoma Collapse << | Phase 1 | Completed | - | Japan ... more >> Novartis Investigative Site Tokyo, Japan Collapse << |
NCT02720510 | Multiple Myeloma | Phase 2 | Terminated(A study was termina... more >>ted due to low enrollment.) Collapse << | - | United States, California ... more >> David Geffen School of Medicine at UCLA UCLA Los Angeles, California, United States, 90095 United States, Florida Memorial West Cancer Center Memorial Cancer Institute Pembroke Pines, Florida, United States, 33028 United States, Georgia Northside Hospital Central Research Dept. Atlanta, Georgia, United States, 30342 United States, Nebraska Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists Omaha, Nebraska, United States, 68124 United States, Texas Brooke Army Medical Center Hematology/Oncology San Antonio, Texas, United States, 78234 Collapse << |
NCT01440582 | Myeloma | Phase 1 | Active, not recruiting | February 1, 2019 | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01034163 | - | - | Completed | - | - |
NCT00891033 | Multiple Myeloma | Phase 1 | Terminated(This study was term... more >>inated because the drug company stopped making the study drug) Collapse << | - | United States, Arkansas ... more >> Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 Collapse << |
NCT01007968 | Advanced Solid Tumors | Phase 1 | Completed | - | United States, Utah ... more >> University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84103 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Sweden Novartis Investigative Site Lund, Sweden, SE-221 85 Novartis Investigative Site Stockholm, Sweden, SE-171 76 Switzerland Novartis Investigative Site St. Gallen, Switzerland, 9007 United Kingdom Novartis Investigative Site Edinburgh, United Kingdom, EH4 2XR Collapse << |
NCT01965353 | Multiple Myeloma in Relapse | Phase 1 | Active, not recruiting | December 2019 | United States, Massachusetts ... more >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Collapse << |
NCT01034163 | Hodgkin's Lymphoma | Phase 3 | Completed | - | - |
NCT00503451 | Non-Hodgkin Lymphoma ... more >> Neoplasms Collapse << | Phase 1 | Completed | - | United States, Nevada ... more >> Nevada Cancer Institute Las Vegas, Nevada, United States, 89135 Netherlands Novartis Investigative Site Rotterdam, Netherlands Collapse << |
NCT00946647 | Myelodysplastic Syndromes ... more >> Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia Collapse << | Phase 1 | Active, not recruiting | June 13, 2019 | - |
NCT00567879 | Breast Cancer | Phase 1 Phase 2 | Terminated(The study was termi... more >>nated early due to insufficient evidence of clinical benefit.) Collapse << | - | United States, California ... more >> University of California at Los Angeles Los Angeles, California, United States, 90095 United States, Colorado University of Colorado Dept. of Univ. of Colorado Aurora, Colorado, United States, 80045 United States, Connecticut Norwalk Hospital Dept of Norwalk Hospital (2) Norwalk, Connecticut, United States, 06856 United States, Maryland VA Maryland Health Care Dept.of GreenbaumCancerCent(3) Baltimore, Maryland, United States, 21201 United States, Missouri The Center for Cancer Care and Research St. Louis, Missouri, United States, 63141 United States, Ohio Ohio State Comprehensive Cancer Center/James Cancer Hospital SC Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital Pittsburgh, Pennsylvania, United States, 15232 Canada, British Columbia Novartis Investigative Site Kelowna, British Columbia, Canada, V1Y 5L3 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H3T 1E2 France Novartis Investigative Site Dijon Cedex, France, 21034 Novartis Investigative Site Paris, France, 75231 Novartis Investigative Site Saint-Herblain Cédex, France, 44805 Germany Novartis Investigative Site Heidelberg, Germany, 69115 Italy Novartis Investigative Site Meldola, FC, Italy, 47014 Novartis Investigative Site Genova, GE, Italy, 16132 Novartis Investigative Site Modena, MO, Italy, 41100 United Kingdom Novartis Investigative Site Birmingham, United Kingdom, B15 2TH Novartis Investigative Site London, United Kingdom, W12 0HS Novartis Investigative Site Manchester, United Kingdom, M20 4BX Collapse << |
NCT01028313 | Chronic Graft-Versus-Host Dise... more >>ase Collapse << | Phase 2 | Withdrawn(A decision was made ... more >>to not move forward with the study. No participants were enrolled or treated.) Collapse << | - | United States, Tennessee ... more >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 Collapse << |
NCT00632489 | - | - | Completed | - | - |
NCT00567879 | - | - | Terminated(The study was termi... more >>nated early due to insufficient evidence of clinical benefit.) Collapse << | - | - |
NCT00777049 | Breast Cancer | Phase 2 | Completed | - | United States, California ... more >> UCLA Los Angeles, California, United States, 90095-1678 Collapse << |
NCT00777049 | - | - | Completed | - | - |
NCT01463046 | Acute Myeloid Leukemia ... more >> Advanced Myelodysplastic Syndrome Collapse << | Phase 1 | Active, not recruiting | December 2018 | United States, California ... more >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 Collapse << |
NCT00594230 | Myelodysplastic Syndromes (MDS... more >>) Collapse << | Phase 2 | Terminated(Per protocol, the r... more >>esults of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.) Collapse << | - | United States, Florida ... more >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Kentucky Consultants in Blood Disorders and Cancer Louisville, Kentucky, United States, 40207 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 Collapse << |
NCT00594230 | - | - | Terminated(Per protocol, the r... more >>esults of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.) Collapse << | - | - |
NCT00632489 | Breast Cancer | Phase 1 | Completed | - | United States, Tennessee ... more >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 Collapse << |
NCT00550277 | Renal Cell Carcinoma | Phase 2 | Completed | - | United States, Florida ... more >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Louisiana Baton Rouge General Medical Center Baton Rouge, Louisiana, United States, 70806 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Nebraska Methodist Cancer Center Omaha, Nebraska, United States, 68114 United States, New Jersey Hematology Oncology Associates of Northern NJ Morristown, New Jersey, United States, 07960 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Peninsula Cancer Institute Newport News, Virginia, United States, 23601 Collapse << |
NCT00570284 | Cancer | Phase 1 | Completed | - | United States, California ... more >> Novartis Investigative Site Los Angeles, California, United States United States, Connecticut Novartis Investigative Site Norwalk, Connecticut, United States United States, Maryland Novartis Investigative Site Rockville, Maryland, United States United States, Massachusetts Novartis Investigative Site Boston, Massachusetts, United States United States, New Hampshire Novartis Investigative Site Lebanon, New Hampshire, United States United States, New York Novartis Investigative Site New York, New York, United States United States, Wisconsin Novartis Investigative Site Madison, Wisconsin, United States Sweden Novartis Investigative Site Stokholm, Sweden Switzerland Novartis Investigative Site Zurich, Switzerland Collapse << |
NCT00550277 | - | - | Completed | - | - |
NCT00739414 | Cancer Advanc... more >>ed Solid Tumor Collapse << | Phase 1 | Completed | - | Japan ... more >> Novartis Investigational Site Aichi prefecture, Japan Novartis Investigational Site Hokkaido, Japan Novartis Investigational Site Hyogo prefecture, Japan Collapse << |
NCT00848523 | Recurrent Malignant Gliomas | Phase 2 | Terminated(insufficient accrua... more >>l) Collapse << | - | United States, New York ... more >> Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates Commack, New York, United States, 11725 Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates Great Neck, New York, United States, 11021 Collapse << |
NCT01301807 | Non-Secretory Plasma Cell Myel... more >>oma Plasmacytosis Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Collapse << | Phase 1 | Active, not recruiting | August 31, 2019 | United States, Texas ... more >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01298934 | Primary Myelofibrosis ... more >> Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Post-Essential Thrombocythemia Related Myelofibrosis Collapse << | Phase 1 Phase 2 | Unknown | July 2015 | United States, New York ... more >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Collapse << |
NCT00743288 | Multiple Myeloma | Phase 1 Phase 2 | Completed | - | United States, California ... more >> Comprehensive Blood and Cancer Center Bakersfield, California, United States, 93309-0633 James R. Berenson MD, Incorporated West Hollywood, California, United States, 90069 United States, Colorado Rocky Mountain Cancer Centers - Denver Midtown Denver, Colorado, United States, 80218 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 Collapse << |
NCT00997399 | Advanced Solid Tumors | Phase 1 | Completed | - | United States, Utah ... more >> University of Utah / Huntsman Cancer Institute Salt Lake City, Utah, United States, 84103 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Novartis Investigative Site Utrecht, Netherlands, 3584CX Switzerland Novartis Investigative Site St. Gallen, Switzerland, 9007 United Kingdom Novartis Investigative Site Merseyside, United Kingdom, L63 4JY Collapse << |
NCT00840346 | Acute Myeloblastic Leukaemia | Phase 1 Phase 2 | Completed | - | Spain ... more >> Hospital Clinic y Provincial de Barcelona Barcelona, Spain Hospital Germans Trías i Pujol Barcelona, Spain Hospital Santa Creu y Sant Pau. Barcelona Barcelona, Spain Hospital 12 de Octubre. Madrid Madrid, Spain Hospital Clínico San Carlos. Madrid Madrid, Spain Hospital Ramón y Cajal. Madrid Madrid, Spain Hospital Morales Messeguer. Murcia Murcia, Spain Hospital Univ. La Fe de Valencia Valencia, Spain Hospital Lozano Blesa. Zaragoza Zaragoza, Spain Collapse << |
NCT01023308 | Multiple Myeloma | Phase 3 | Completed | - | - |
NCT01613976 | Myelodysplastic Syndromes (MDS... more >>) Chronic Myelomonocytic Leukemia (CMML) Acute Myeloid Leukemia (AML) Collapse << | Phase 1 | Completed | - | Japan ... more >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 466-8650 Novartis Investigative Site Nagoya, Aichi, Japan, 460-0001 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0017 Novartis Investigative Site Sendai-city, Miyagi, Japan, 980-8574 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 104-0045 Novartis Investigative Site Kyoto, Japan, 602-8566 Collapse << |
NCT01023308 | - | - | Completed | - | - |
NCT01433445 | Idiopathic Myelofibrosis ... more >> Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis Collapse << | Phase 1 | Active, not recruiting | December 31, 2018 | France ... more >> Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Mainz, Germany, 55131 Ireland Novartis Investigative Site Dublin, Ireland, DUBLIN 8 Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Novartis Investigative Site Varese, VA, Italy, 21100 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT Collapse << |
NCT01013597 | Thyroid Carcinoma | Phase 2 | Completed | - | United States, Wisconsin ... more >> St. Vincent Regional Cancer Center CCOP Green Bay, Wisconsin, United States, 54301 University of Wisconsin - Madison Madison, Wisconsin, United States, 53792 Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Collapse << |
NCT00663832 | Prostate Cancer | Phase 1 | Completed | - | United States, Maryland ... more >> Novartis Investigative Site Rockville, Maryland, United States, 20850 United States, Michigan Novartis Investigative Site Detroit, Michigan, United States, 48201 United States, Missouri Novartis Investigative Site St. Louis, Missouri, United States, 63110 United States, Nevada Novartis Investigative Site Las Vegas, Nevada, United States, 89135 United States, New York Novartis Investigative Site New York, New York, United States, 10021 United States, North Carolina Novartis Investigative Site Durham, North Carolina, United States, 27710 United States, Oregon Novartis Investigative Site Portland, Oregon, United States, 97239 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1L8 Canada, Ontario Novartis Investigative Site Hamilton, Ontario, Canada, L8V 5C2 Collapse << |
NCT00670553 | Prostate Cancer ... more >> Head & Neck Cancer Esophageal Cancer Collapse << | Phase 1 | Completed | - | Belgium ... more >> Novartis Investigative Site Liege, Belgium Collapse << |
NCT00743288 | - | - | Completed | - | - |
NCT01651039 | Multiple Myeloma | Phase 2 | Completed | - | United States, New York ... more >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Collapse << |
NCT01013597 | - | - | Completed | - | - |
NCT01136499 | Soft Tissue Sarcoma | Phase 2 | Completed | - | France ... more >> Centre Léon Berard Lyon, France Collapse << |
NCT01549431 | Multiple Myeloma | Phase 1 | Active, not recruiting | December 2018 | United States, California ... more >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, Georgia Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 Collapse << |
NCT01523834 | Diffuse Large B-cell Lymphoma | Phase 2 | Completed | - | Italy ... more >> Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo Alessandria, Italy, 15121 Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola Bologna, Italy, 40138 Spedali Civili Brescia, Italy Ematologia I, A.O.U. San Martino Genova, Italy, 16132 Ospedale Umberto I - DH Oncoematologico Nocera Inferiore, Italy Divisione di Ematologia Università Avogadro Novara, Italy AO Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy, 90146 A.O. Città della Salute e della Scienza (Ematologia Univ) Torino, Italy A.O. Città della salute e della scienza (S.C. Ematologia) Torino, Italy AO Universitaria di Udine Udine, Italy Collapse << |
NCT01321346 | Lymphoblastic Leukemia, Acute,... more >> Childhood Myelogenous Leukemia, Acute, Childhood Hodgkin's Disease Non-Hodgkin's Lymphoma Collapse << | Phase 1 | Completed | - | - |
NCT01651039 | - | - | Completed | - | - |
NCT00901147 | Peripheral T-cell Lymphoma (No... more >>t Otherwise Specified) Angioimmunoblastic T-cell Lymphoma Extranodal NK/T-cell Lymphoma Nasal Type Enteropathy- Type T-cell Lymphoma Hepatosplenic T-cell Lymphoma Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant Collapse << | Phase 2 | Completed | - | Korea, Republic of ... more >> Samsung Medical Centre Seoul, Korea, Republic of, 135-710 Malaysia Subang Jaya Medical Centre Subang Jaya, Selangor, Malaysia, 47500 Hospital Universiti Kebangsaan Malaysia ( HUKM ) Kuala Lumpur, Malaysia, 56000 Singapore National Cancer Center Singapore, Singapore, 169608 Singapore General Hospital Singapore, Singapore, 169608 Collapse << |
NCT01658241 | Nodal Lymphoma ... more >> Lymphoma With Cutaneous Involvement Lymphoma in Leukemic Phase Marrow Involvement With Lymphoma Multiple Myeloma Collapse << | Phase 2 | Active, not recruiting | July 2018 | Australia, Victoria ... more >> Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3002 Collapse << |
NCT00925132 | - | - | Terminated(Change in the numbe... more >>r of approved drugs for metastatic melanoma) Collapse << | - | - |
NCT02722941 | Multiple Myeloma | Phase 2 | Recruiting | June 2021 | United States, Florida ... more >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Caitlyn Ward 813-745-1344 caitlyn.ward@moffitt.org Contact: Taiga Nishihori 813-745-8156 taiga.nishihori@moffitt.org Principal Investigator: Taiga Nishihori, M.D. Sub-Investigator: Melissa Alsina, M.D. Sub-Investigator: Claudio Anasetti, M.D. Sub-Investigator: Ernesto Ayala, M.D. Sub-Investigator: Rachid Baz, M.D. Sub-Investigator: Brian Betts, M.D. Sub-Investigator: Hugo Fernandez, M.D. Sub-Investigator: Jingsong Zhang, M.D., Ph.D. Sub-Investigator: Mohamed Kharfan-Dabaja, M.D. Sub-Investigator: Farhad Khimani, M.D. Sub-Investigator: Frederick Locke, M.D. Sub-Investigator: Asmita Mishra, M.D. Sub-Investigator: Jose Ochoa-Bayona, M.D. Sub-Investigator: Lia Perez, M.D. Sub-Investigator: Joseph Pidala, M.D., Ph.D. Sub-Investigator: Kenneth Shain, M.D., Ph.D. Collapse << |
NCT00742027 | Classical Hodgkin's Lymphoma (... more >>i.e. Nodular Sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte-depleted) Collapse << | Phase 2 | Completed | - | - |
NCT00925132 | Metastatic Melanoma | Phase 1 Phase 2 | Terminated(Change in the numbe... more >>r of approved drugs for metastatic melanoma) Collapse << | - | United States, Iowa ... more >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 Collapse << |
NCT03632317 | Glioma Diffus... more >>e Intrinsic Pontine Glioma Collapse << | Phase 2 | Recruiting | September 2025 | United States, Michigan ... more >> University of Michigan Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Carl Koschmann, M.D. 734-615-2736 ckoschma@umich.edu Principal Investigator: Carl Koschmann, MD Collapse << |
NCT01460940 | Adult Lymphocyte Depletion Hod... more >>gkin Lymphoma Adult Lymphocyte Predominant Hodgkin Lymphoma Adult Mixed Cellularity Hodgkin Lymphoma Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma Adult Nodular Sclerosis Hodgkin Lymphoma Recurrent Adult Hodgkin Lymphoma Collapse << | Phase 2 | Completed | - | United States, Missouri ... more >> Washington University Saint Louis, Missouri, United States, 63110 United States, Ohio The Ohio State University Medical Center Columbus, Ohio, United States, 43210 Collapse << |
NCT01282476 | - | - | Terminated(slow accrual) | - | - |
NCT01460940 | - | - | Completed | - | - |
NCT01065467 | Melanoma Mali... more >>gnant Melanoma Collapse << | Phase 1 | Completed | - | United States, Massachusetts ... more >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Collapse << |
NCT01282476 | Diffuse Large B Cell Lymphoma | Phase 2 | Terminated(slow accrual) | - | United States, Massachusetts ... more >> Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Collapse << |
NCT00985946 | Neuroendocrine Tumors | Phase 2 | Terminated(Study did not meet ... more >>statistical requirements to continue.) Collapse << | - | United States, Wisconsin ... more >> University of Wisconsin, Madison Madison, Wisconsin, United States, 53792 Collapse << |
NCT00985946 | - | - | Terminated(Study did not meet ... more >>statistical requirements to continue.) Collapse << | - | - |
NCT00967044 | - | - | Completed | - | - |
NCT01504776 | Mantle Cell Lymphoma | Phase 1 | Completed | - | United States, Georgia ... more >> Georgia Regents University Augusta, Georgia, United States, 30912 Collapse << |
NCT01693601 | Myelofibrosis | Phase 1 Phase 2 | Active, not recruiting | February 2019 | United States, New York ... more >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Collapse << |
NCT01336842 | Solid Tumors ... more >>Non-Small Cell Lung Cancer (NSCLC) Collapse << | Phase 1 | Completed | - | United States, California ... more >> University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 Collapse << |
NCT00931762 | Primary Myelofibrosis ... more >> Post-Polycythemia Vera Post-Essential Thrombocytopenia Collapse << | Phase 2 | Completed | - | United States, Arizona ... more >> Mayo Clinic - Scottsdale Scottsdale, Arizona, United States, 85259 United States, California City of Hope National Medical Center Duate, California, United States, 91010 Stanford Comprehensive Cancer Center Stanford, California, United States, 94305 United States, Georgia Medical College of Georgia Augusta, Georgia, United States, 30912 United States, Illinois Northwestern University Feinberg School of Medicine Chicago, Illinois, United States, 60611 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic - Rochester Rochester, Minnesota, United States, 55905 United States, New York New York Prebyterian Hospital - Weill Cornell Medical College New York, New York, United States, 10021 Collapse << |
NCT01451268 | Myelodysplastic Syndrome ... more >> Acute Myeloid Leukemia Collapse << | Phase 1 Phase 2 | Active, not recruiting | April 2018 | Germany ... more >> University Hospital Düsseldorf Düsseldorf, Germany, 40225 University Hospital Essen Essen, Germany, 45147 University Hospital Frankfurt Frankfurt am Main, Germany, 60590 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 University Hospital Mainz Mainz, Germany, 55131 University Hospital Marburg Marburg, Germany, 35043 Collapse << |
NCT02568943 | - | - | - | - | - |
NCT01115036 | Recurrent Glioblastoma | Phase 2 | Withdrawn(No subjects were enr... more >>olled on this study, so study was closed and IND withdrawn.) Collapse << | April 2012 | United States, North Carolina ... more >> Duke University Medical Center Durham, North Carolina, United States, 27710 Collapse << |
NCT00967044 | Lymphoma | Phase 1 Phase 2 | Completed | - | United States, Texas ... more >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01680094 | HIV Infection | Phase 1 Phase 2 | Completed | - | Denmark ... more >> Department of Infectious Diseases, Aarhus University Hospital Aarhus, Denmark, 8200 Collapse << |
NCT02032810 | Melanoma Skin... more >> Cancer Collapse << | Phase 1 | Active, not recruiting | December 2019 | United States, Florida ... more >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Collapse << |
NCT01242774 | Acute Myeloid Leukemia (AML) | Phase 1 | Completed | - | United States, California ... more >> Stanford University Medical Center Stanford U Stanford, California, United States, 94304 United States, Massachusetts Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr Boston, Massachusetts, United States, 02115 United States, Ohio Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2) Charleston, South Carolina, United States, 29425 United States, Tennessee Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3 Nashville, Tennessee, United States, 37212 Germany Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site Ulm, Germany, 89081 Spain Novartis Investigative Site Salamanca, Castilla y Leon, Spain, 37007 Novartis Investigative Site Barcelona, Spain, 08025 Collapse << |
NCT02717455 | Glioma | Phase 1 | Recruiting | October 1, 2019 | United States, California ... more >> Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90026 Contact: Girish Dhall, MD 323-361-4629 gdhall@chla.usc.edu Contact: Kelley Haley, BSN,RN,CCRP 323-361-2480 khaley@chla.usc.edu Principal Investigator: Girish Dhall, MD Stanford University and Lucile Packard Children's Hospital Recruiting Palo Alto, California, United States, 94304 Contact: Paul Graham Fisher, MD 650-721-5889 pfisher@stanford.edu Contact: Leah White 650-725-4708 lwhite15@stanford.edu Principal Investigator: Paul Graham Fisher, MD United States, District of Columbia Children's National Medical Center Recruiting Washington, D.C., District of Columbia, United States, 20010 Contact: Roger Packer, MD 202-884-2120 rpacker@cnmc.org Contact: Chad Stephans 202-476-4481 CStephan@childrensnational.org Principal Investigator: Roger Packer, MD United States, Illinois Ann & Robert H. Lurie Children's Hospital of Chicago Recruiting Chicago, Illinois, United States, 60611 Contact: Stewart Goldman, MD 312-227-4844 sgoldman@luriechildrens.org Contact: Emily Golbeck 312-227-4858 egolbeck@luriechildrens.org Principal Investigator: Stewart Goldman, MD United States, Maryland National Cancer Institute Recruiting Bethesda, Maryland, United States, 20892 Contact: Kathy Warren, MD 301-435-4683 warrenk@mail.nih.gov Contact: Sonja Crandon, RN,BSN,PMP 301-496-8009 Sonja.crandon@nih.gov Principal Investigator: Kathy Warren, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Ira Dunkel, MD 212-639-2153 dunkeli@mskcc.org Contact: Ryan Turner 646-888-5723 turnerr@mskcc.org Principal Investigator: Ira Dunkel, MD United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Maryam Fouladi, MD 513-803-0721 maryam.fouladi@cchmc.org Contact: CCHMC Cancer Line 513-636-2799 Cancer@cchmc.org Principal Investigator: Maryam Fouladi, MD United States, Pennsylvania Children's Hospital of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: Arthur 'Kim' Ritchey, MD 412-692-6794 ritcheyak@upmc.edu Contact: Sharon DiBridge 412-692-7070 sharon.dibridge@chp.edu Principal Investigator: Arthur 'Kim' Ritchey, MD United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Alberto Broniscer, MD 901-595-4925 alberto.broniscer@stjude.org Contact: Dillon Robinson 901-595-5922 Dillon.Robinson@stjude.org Principal Investigator: Alberto Broniscer, MD United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Patricia Baxter, MD 832-824-4681 pabaxter@txch.org Contact: Susan Burlingame, CCRP 832-824-1532 sxburlin@txch.org Principal Investigator: Patricia Baxter, MD Collapse << |
NCT01802879 | Hematologic Neoplasms | Phase 2 | Active, not recruiting | November 22, 2018 | United States, California ... more >> City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1) Duarte, California, United States, 91010-3000 United States, Georgia Georgia Regents University SC-2 Augusta, Georgia, United States, 30912 United States, Massachusetts Dana Farber Cancer Institute Reg. Ped Boston, Massachusetts, United States, 02215 United States, Utah University of Utah / Huntsman Cancer Institute SC-2 Salt Lake City, Utah, United States, 84103 Israel Novartis Investigative Site Jerusalem, Israel, 91120 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Spain Novartis Investigative Site Salamanca, Castilla Y Leon, Spain, 37007 Collapse << |
NCT01496118 | Multiple Myeloma | Phase 1 Phase 2 | Active, not recruiting | December 2019 | United States, Colorado ... more >> Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists South Fort Myers, Florida, United States, 33916 Woodlands Medical Specialists Pensacola, Florida, United States, 32503 Florida Cancer Specialists North Saint Petersburg, Florida, United States, 33705 United States, Indiana Providence Medical Group Terre Haute, Indiana, United States, 47802 RHHP/Hope Cancer Center Terre Haute, Indiana, United States, 47802 United States, Missouri Research Medical Center Kansas City, Missouri, United States, 64132 United States, New Jersey Hematology-Oncology Associates - Northern NJ Morristown, New Jersey, United States, 07962 United States, Ohio Oncology Hematology Care, Inc. Cincinnati, Ohio, United States, 45242 United States, Oklahoma Cancer Centers of Southwest Oklahoma Lawton, Oklahoma, United States, 73505 United States, Tennessee Tennessee Oncology-Chattanooga Chattanooga, Tennessee, United States, 37404 Tennessee Oncology Nashville, Tennessee, United States, 37205 United States, Texas The Center for Cancer and Blood Disorders Fort Worth, Texas, United States, 76104 Collapse << |
NCT01245179 | Sickle Cell Disease | Phase 1 | Active, not recruiting | July 2023 | United States, Georgia ... more >> Augusta University Augusta, Georgia, United States, 30912 Collapse << |
靶点 | Description | IC50 |
---|---|---|
HDAC | IC50:5nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网